2013
DOI: 10.1253/circj.cj-13-0307
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Low-Dose Aspirin on Primary Prevention of Cardiovascular Events in Japanese Diabetic Patients at High Risk

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 26 publications
0
7
0
Order By: Relevance
“…The ADA has recommended that aspirin use for the primary ASCVD prevention should be considered 824 ) for high-risk men and women aged ≥ 50 years. However, the JPAD studies conducted in Japan did not show any protective effects of aspirin on cardiovascular events in patients with DM 825 , 826 ) .…”
Section: Comprehensive Risk Managementmentioning
confidence: 92%
“…The ADA has recommended that aspirin use for the primary ASCVD prevention should be considered 824 ) for high-risk men and women aged ≥ 50 years. However, the JPAD studies conducted in Japan did not show any protective effects of aspirin on cardiovascular events in patients with DM 825 , 826 ) .…”
Section: Comprehensive Risk Managementmentioning
confidence: 92%
“…men >50 years of age and women >60 years who had ≥1 additional CV risk factor). [42] Several meta-analyses of aspirin data in patients with diabetes without known CVD and patients with diabetes and CHD have consistently shown only modest reductions in CV-related (1-9%), [34,[43][44][45][46][47] all-cause mortality (1-7%), [34,[43][44][45][46][47][48][49] stroke (2-30%), [33,34,[43][44][45][46][47][48][49][50] myocardial infarction (MI) (5-10%), [33,34,[43][44][45][46][47][48][49][50] and major CV events (8-11%) [34,[43][44][45]47,48] with aspirin ( Figure 4). In a single meta-analysis of seven randomized trials, the number needed to treat for primary prevention of a major adverse CV event with aspirin in patients with diabetes was 92, with an estimated likelihood of being helped versus harmed of 6 [34]; similar information for patients with diabetes and CVD are not currently available.…”
Section: Aspirin: Antiplatelet Effects and Pharmacokineticsmentioning
confidence: 99%
“…Of those, antiplatelet drugs such as low-dose aspirin and clopidogrel are used for prevention of cerebrovascular disease and coronary arterial disease 1, 2, 3, 4. On the other hand, anticoagulant drugs, including warfarin and direct oral anticoagulants (DOACs) are given for a variety of clinical conditions, such as prevention of recurrent venous thromboembolism and stroke in patients with atrial fibrillation 5, 6, 7, 8.…”
Section: Introductionmentioning
confidence: 99%